Aptamer Group PLC Placing and Subscription, PDMR Dealing and TVR (9603M)
September 19 2023 - 8:35AM
UK Regulatory
TIDMAPTA
RNS Number : 9603M
Aptamer Group PLC
19 September 2023
19 September 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Placing and Subscription to raise GBP310,772
PDMR Dealing
Total Voting Rights
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
today announces that it has raised GBP310,772 through the issue of
28,251,956 new Ordinary Shares by way of a subscription and a
placing by Turner Pope to certain existing shareholders at 1.1p per
share (the "Issue Price") (together, the "Fundraise").
The Fundraise was initiated following approaches from existing
non-UK shareholders who could not be contacted in time to
participate in the August 2023 fundraise and extended to take
advantage of demand from other existing shareholders using the
Company's remaining net authorised unissued share capital.
The Fundraise includes a subscription by Dr Adam Hargreaves, a
non-executive director of the Company, for 5,000,000 new Ordinary
Shares for a total investment of GBP55,000. Following this further
investment, Dr Hargreaves is now interested in 22,500,000 Ordinary
Shares representing 4.81 per cent of the enlarged issued share
capital.
In addition, an existing investor, Mr Nicholas Slater, is
investing GBP50,000 in the Fundraise for 4,545,454 new Ordinary
Shares, taking his holding to 26,045,454 Ordinary Shares
representing 5.57% of the enlarged issued share capital.
The net proceeds will be ringfenced to support research and
development (R&D) activities within the business, including the
ongoing process improvements. R&D work was reduced as part of
the Company's new strategy to support cost-cutting in August. While
higher-risk development activities will still aim to be funded by
grants, the new funds will enable internal validation of the
technology in key focus areas.
Total Voting Rights
Application for the admission of the new Ordinary Shares to
trading on AIM ("Admission") has been made and Admission is
expected on Monday, 25 September 2023, following which the total
number of shares in issue and total voting rights will be
467,343,673. The Group does not hold any shares in treasury and,
therefore, the above figure may be used by shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in the Company.
- ENDS -
For further information, please contact:
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Mark Brady / Adam Dawes +44 (0) 20 3368 3550
-----------------------
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
-----------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK
domestic law by virtue of the European Union (Withdrawal) Act
2018.
About Aptamer Group plc
Aptamer develops custom affinity binders through its proprietary
Optimer (R) platform to enable new approaches in therapeutics,
diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life
science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion. Optimer binders are
engineered to address many of the issues found with alternative
affinity molecules, such as antibodies, and offer new, innovative
solutions to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered projects for global pharma
companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support
discovery and development across the Life Sciences.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Adam Hargreaves
-------------------------------- ---------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Non-Executive Director - PDMR
-------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Aptamer Group plc
-------------------------------- ---------------------------------------
b) LEI 213800Y4XGH3WJNBE686
-------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary shares of GBP0.001 each
the financial
instrument, type
of instrument
Identification GB00BNRRP542
code
b) Nature of the Acquisition of shares
transaction
-------------------------------- ---------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1.1p 5,000,000
----------
-------------------------------- ---------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
e) Date of the transaction 19 September 2023
-------------------------------- ---------------------------------------
f) Place of the transaction Off market
-------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOESFLFDUEDSEDU
(END) Dow Jones Newswires
September 19, 2023 09:35 ET (13:35 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024